Profile data is unavailable for this security.
About the company
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
- Revenue in USD (TTM)0.00
- Net income in USD-7.61m
- Incorporated2014
- Employees10.00
- LocationMonopar Therapeutics Inc1000 Skokie Blvd Ste 350WILMETTE 60091-1146United StatesUSA
- Phone+1 (847) 388-0349
- Fax+1 (302) 655-5049
- Websitehttps://www.monopartx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Check Cap Ltd | 0.00 | -17.57m | 11.76m | 85.00 | -- | 0.4965 | -- | -- | -3.00 | -3.00 | 0.00 | 4.05 | 0.00 | -- | -- | -- | -49.87 | -54.23 | -53.46 | -60.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.06 | -- | -2.46 | -- |
Oncotelic Therapeutics Inc | 70.00k | -7.79m | 11.99m | 22.00 | -- | 1.01 | -- | 171.29 | -0.0197 | -0.0197 | 0.0002 | 0.0296 | 0.0021 | -- | 3.61 | 3,181.82 | -24.46 | -25.03 | -49.25 | -48.76 | -- | -- | -11,536.00 | -1,692.93 | -- | -0.4696 | 0.5341 | -- | -- | -- | -255.12 | -- | -- | -- |
Enzon Pharmaceuticals Inc | 0.00 | 221.00k | 12.03m | 0.00 | 54.38 | 3.65 | -- | -- | 0.003 | 0.003 | 0.00 | 0.624 | 0.00 | -- | -- | -- | 3.21 | -0.8654 | 3.24 | -0.8851 | -- | -- | -- | -159.43 | -- | -- | 0.00 | -- | -100.00 | -- | 106.71 | -55.86 | -- | -- |
Cardio Diagnostics Holdings Inc | 33.00k | -11.51m | 12.43m | 7.00 | -- | 3.90 | -- | 376.72 | -0.8257 | -0.8257 | 0.0021 | 0.1404 | 0.0051 | -- | -- | 4,714.29 | -178.70 | -- | -325.81 | -- | -- | -- | -34,872.12 | -- | -- | -4.84 | 0.0715 | -- | 1,696.84 | -- | -79.72 | -- | -- | -- |
Bullfrog AI Holdings, Inc. | 65.00k | -5.95m | 12.48m | 4.00 | -- | 1.83 | -- | 192.04 | -0.8903 | -0.8903 | 0.0097 | 0.8667 | 0.0094 | -- | -- | 16,250.00 | -85.49 | -- | -103.85 | -- | 92.00 | -- | -9,129.42 | -- | -- | -278.20 | 0.0694 | -- | 550.00 | -- | -91.11 | -- | -- | -- |
Monopar Therapeutics Inc | 0.00 | -7.61m | 12.59m | 10.00 | -- | 1.68 | -- | -- | -0.5289 | -0.5289 | 0.00 | 0.4277 | 0.00 | -- | -- | 0.00 | -73.36 | -54.07 | -92.67 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
BioRestorative Therapies Inc | 149.50k | -6.96m | 12.66m | 11.00 | -- | 0.8737 | -- | 84.68 | -1.49 | -1.49 | 0.0302 | 2.14 | 0.0093 | -- | 5.86 | 13,590.91 | -43.44 | -192.11 | -49.49 | -329.32 | -- | -- | -4,653.34 | -19,116.15 | -- | -- | 0.00 | -- | 21.70 | 5.61 | 43.67 | -- | 67.77 | -- |
Imunon Inc | 0.00 | -18.85m | 12.79m | 33.00 | -- | 1.50 | -- | -- | -2.02 | -2.02 | 0.00 | 0.9041 | 0.00 | -- | -- | 0.00 | -66.82 | -50.18 | -91.53 | -60.27 | -- | -- | -- | -5,725.88 | -- | -- | 0.00 | -- | -100.00 | -- | 45.64 | -- | 26.69 | -- |
Avalo Therapeutics Inc | 1.45m | -142.88m | 13.02m | 19.00 | -- | -- | -- | 8.98 | -318.69 | -318.69 | 3.02 | -97.75 | 0.0181 | -- | 3.25 | 76,315.79 | -178.64 | -99.64 | -- | -154.42 | 54.90 | 84.69 | -9,853.73 | -613.58 | -- | -0.2415 | -- | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
Galecto Inc | 0.00 | -30.83m | 13.46m | 13.00 | -- | 0.4779 | -- | -- | -1.15 | -1.15 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -63.50 | -48.46 | -78.33 | -52.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.77 | -- | -- | -- |
Kiora Pharmaceuticals Inc | 16.00m | 2.28m | 13.63m | 12.00 | -- | 0.3836 | 5.87 | 0.8522 | -14.38 | -14.38 | 10.88 | 11.96 | 0.5427 | -- | 8.64 | 1,333,333.00 | 9.52 | -70.52 | 10.17 | -81.86 | -- | -- | 17.55 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Millennium Management LLCas of 31 Mar 2024 | 192.38k | 1.10% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 45.17k | 0.26% |
Geode Capital Management LLCas of 31 Mar 2024 | 41.20k | 0.24% |
HRT Financial LLCas of 31 Mar 2024 | 32.11k | 0.18% |
Gerber LLCas of 31 Mar 2024 | 28.01k | 0.16% |
Virtu Americas LLCas of 31 Mar 2024 | 23.83k | 0.14% |
Rappaport Reiches Capital Management LLCas of 31 Mar 2024 | 10.70k | 0.06% |
Tower Research Capital LLCas of 31 Mar 2024 | 7.86k | 0.05% |
Strategic Advisers LLCas of 31 Mar 2024 | 5.50k | 0.03% |
NewEdge Advisors LLCas of 31 Mar 2024 | 3.00k | 0.02% |